132 related articles for article (PubMed ID: 18830613)
41. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
Kim SH; Kwon HC; Oh SY; Lee DM; Lee S; Lee JH; Roh MS; Kim DC; Park KJ; Choi HJ; Kim HJ
Am J Clin Oncol; 2009 Feb; 32(1):38-43. PubMed ID: 19194123
[TBL] [Abstract][Full Text] [Related]
42. Design, synthesis and anticancer potential of NSC-319745 hydroxamic acid derivatives as DNMT and HDAC inhibitors.
Yuan Z; Sun Q; Li D; Miao S; Chen S; Song L; Gao C; Chen Y; Tan C; Jiang Y
Eur J Med Chem; 2017 Jul; 134():281-292. PubMed ID: 28419930
[TBL] [Abstract][Full Text] [Related]
43. Histone deacetylase inhibitor potentiates anticancer effect of docetaxel via modulation of Bcl-2 family proteins and tubulin in hormone refractory prostate cancer cells.
Hwang JJ; Kim YS; Kim MJ; Kim DE; Jeong IG; Kim CS
J Urol; 2010 Dec; 184(6):2557-64. PubMed ID: 21030039
[TBL] [Abstract][Full Text] [Related]
44. JNJ-26481585, a novel "second-generation" oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity.
Arts J; King P; Mariën A; Floren W; Beliën A; Janssen L; Pilatte I; Roux B; Decrane L; Gilissen R; Hickson I; Vreys V; Cox E; Bol K; Talloen W; Goris I; Andries L; Du Jardin M; Janicot M; Page M; van Emelen K; Angibaud P
Clin Cancer Res; 2009 Nov; 15(22):6841-51. PubMed ID: 19861438
[TBL] [Abstract][Full Text] [Related]
45. Discovery of PAT-1102, a novel, potent and orally active histone deacetylase inhibitor with antitumor activity in cancer mouse models.
Hiriyan J; Shivarudraiah P; Gavara G; Annamalai P; Natesan S; Sambasivam G; Sukumaran SK
Anticancer Res; 2015 Jan; 35(1):229-37. PubMed ID: 25550555
[TBL] [Abstract][Full Text] [Related]
46. Development and Applicability of Integrative Tumor Response Assays for Metastatic Colorectal Cancer.
Yoon YS; Kim CW; Roh SA; Cho DH; Kim TW; Kim MB; Kim JC
Anticancer Res; 2017 Mar; 37(3):1297-1303. PubMed ID: 28314295
[TBL] [Abstract][Full Text] [Related]
47. Discovery and preliminary evaluation of 2-aminobenzamide and hydroxamate derivatives containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors.
Cai J; Wei H; Hong KH; Wu X; Cao M; Zong X; Li L; Sun C; Chen J; Ji M
Eur J Med Chem; 2015; 96():1-13. PubMed ID: 25874326
[TBL] [Abstract][Full Text] [Related]
48. Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients.
Falcone A; Di Paolo A; Masi G; Allegrini G; Danesi R; Lencioni M; Pfanner E; Comis S; Del Tacca M; Conte P
J Clin Oncol; 2001 Aug; 19(15):3456-62. PubMed ID: 11481350
[TBL] [Abstract][Full Text] [Related]
49. Predicting 5-FU sensitivity using human colorectal cancer specimens: comparison of tumor dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferase activities with in vitro chemosensitivity to 5-FU.
Isshi K; Sakuyama T; Gen T; Nakamura Y; Kuroda T; Katuyama T; Maekawa Y
Int J Clin Oncol; 2002 Dec; 7(6):335-42. PubMed ID: 12494248
[TBL] [Abstract][Full Text] [Related]
50. [Irinotecan monotherapy in the treatment of colorectal cancers: results of phase II trials].
Van Cutsem E; Peeters M
Bull Cancer; 1998 Dec; Spec No():33-7. PubMed ID: 9932082
[TBL] [Abstract][Full Text] [Related]
51. Capecitabine: a review.
Walko CM; Lindley C
Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
[TBL] [Abstract][Full Text] [Related]
52. Functional characteristics and gene expression profiles of primary acute myeloid leukaemia cells identify patient subgroups that differ in susceptibility to histone deacetylase inhibitors.
Stapnes C; Ryningen A; Hatfield K; Øyan AM; Eide GE; Corbascio M; Kalland KH; Gjertsen BT; Bruserud Ø
Int J Oncol; 2007 Dec; 31(6):1529-38. PubMed ID: 17982680
[TBL] [Abstract][Full Text] [Related]
53. [Irinotecan in combination for colon cancer].
Ducreux M; Gil-Delgado M; André T; Ychou M; de Gramond A; Khayat D
Bull Cancer; 1998 Dec; Spec No():43-6. PubMed ID: 9932084
[TBL] [Abstract][Full Text] [Related]
54. 5-Fluorouracil potentiates the anti-cancer effect of oxaliplatin on Colo320 colorectal adenocarcinoma cells.
Berindan-Neagoe I; Braicu C; Pileczki V; Cojocneanu Petric R; Miron N; Balacescu O; Iancu D; Ciuleanu T
J Gastrointestin Liver Dis; 2013 Mar; 22(1):37-43. PubMed ID: 23539389
[TBL] [Abstract][Full Text] [Related]
55. Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy.
Lee JJ; Kim TM; Yu SJ; Kim DW; Joh YH; Oh DY; Kwon JH; Kim TY; Heo DS; Bang YJ; Kim NK
Jpn J Clin Oncol; 2004 Jul; 34(7):400-4. PubMed ID: 15342667
[TBL] [Abstract][Full Text] [Related]
56. A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.
Jones P; Altamura S; De Francesco R; Paz OG; Kinzel O; Mesiti G; Monteagudo E; Pescatore G; Rowley M; Verdirame M; Steinkühler C
J Med Chem; 2008 Apr; 51(8):2350-3. PubMed ID: 18370373
[TBL] [Abstract][Full Text] [Related]
57. Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma.
Heider U; Kaiser M; Sterz J; Zavrski I; Jakob C; Fleissner C; Eucker J; Possinger K; Sezer O
Eur J Haematol; 2006 Jan; 76(1):42-50. PubMed ID: 16343270
[TBL] [Abstract][Full Text] [Related]
58. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen.
André T; Bensmaine MA; Louvet C; François E; Lucas V; Desseigne F; Beerblock K; Bouché O; Carola E; Merrouche Y; Morvan F; Dupont-André G; de Gramont A
J Clin Oncol; 1999 Nov; 17(11):3560-8. PubMed ID: 10550155
[TBL] [Abstract][Full Text] [Related]
59. Modified Irinotecan/5FU/Leucovorin therapy in advanced colorectal cancer and predicting therapeutic efficacy by expression of tumor-related enzymes.
Yanagisawa Y; Maruta F; Iinuma N; Ishizone S; Koide N; Nakayama J; Miyagawa S
Scand J Gastroenterol; 2007 Apr; 42(4):477-84. PubMed ID: 17454858
[TBL] [Abstract][Full Text] [Related]
60. Methods and non-cancer applications of HDAC inhibition.
Wiest O
Curr Top Med Chem; 2009; 9(3):226. PubMed ID: 19355986
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
